



PRESS RELEASE

MaxiVAX announces promising results from its phase 1 anti-cancer clinical trial

- **Novel active and sustained anti-cancer vaccination therapy is safe and well tolerated**
- **Personalized therapy applicable to all cancer types**
- **Phase 2 trial to start in Switzerland in 2H 2016**

Geneva, Switzerland – 07 April 2016 – MaxiVAX SA, a private Swiss biotech company, today announced promising results from a ground-breaking clinical phase 1 trial at the Geneva University Hospital (HUG) with its proprietary cancer vaccination product, MVX-ONCO-1, in 15 patients suffering from various solid cancers at an advanced stage. Based on these results, the company will start a phase 2 trial in head and neck cancer in Switzerland in the second half of 2016 and is evaluating trials in other cancer types.

MVX-ONCO-1 is a unique product combining a vaccine against the complete tumor cell with an immune system boosting agent provided in a sustained manner. The objective of this study was to assess the safety and tolerability of MVX-ONCO-1, administered under the skin in 15 patients with advanced metastatic solid tumors in progression who were no longer amenable to standard therapy. Treatment duration was 8 weeks, with 6 vaccine injections and 6 subcutaneous implantations of the immune booster.

The results demonstrate that MVX-ONCO-1 is safe and well tolerated. There were no adverse events related to the product itself, as assessed by the treating physician. Furthermore, encouraging efficacy results were observed particularly in those patients with a more robust immune system. The results will be presented at the Swiss Biotech Day to be held in Basel on 12 April 2016.

Dr Nicolas Mach MD, Chief Scientific Officer, said: “We are delighted with these promising results which validate the safety and tolerability of this potentially novel therapy for treating cancer patients who to date faced a bleak prognosis. The vast majority of individuals suffering from cancer with local infiltration or metastasis will die from their malignancy within three years despite the currently available therapies.”

He continued: “MVX-ONCO-1 is the first personalized cell-based cancer immunotherapy using encapsulation cell technology. This reprograms and boosts the patient’s own immune system to fight cancer. Therapy is individualized and can be applied to any cancer type.”

Dimitrios Goundis PhD, Chief Executive Officer, commented: “These encouraging results underlie our confidence in taking MVX-ONCO-1 into a number of cancer indications, of which the first will be a phase 2 trial in head and neck cancer in Switzerland, starting later this year. Moreover the benign safety profile of MVX-ONCO-1 makes it an ideal candidate for combination therapies with other anti-tumor agents such as checkpoint inhibitors.”

About MVX-ONCO-1

MaxiVAX's novel Immuno-Oncology therapeutic vaccination is based on triggering the patient's own natural immune response mechanism via an innovative and proprietary technology in order to eliminate cancer cells. MVX-ONCO-1 has been classified as an Advanced Therapeutic Medicinal Product by the European Medicines Agency (EMA).

MVX-ONCO-1 is a product that contains two distinct biological entities:

1) Vaccine: administered by sub-cutaneous injection, using the patient's own irradiated cancer cells as vaccine antigens, with a key benefit of using the entire set of tumor antigens from the patient's own cells.

2) Immune boosting agent: an immune boosting agent (GM-CSF: granulocyte macrophage-colony stimulating factor) is delivered at the site of vaccination in a sustained manner, via genetically reprogrammed cells, encapsulated in a small biocompatible capsule. Two capsules, which are essential to protect the GM-CSF producing cells, are placed underneath the skin at the same site as the vaccine injection. After 1 week the capsules are removed.

The treatment is repeated for a total of 6 immunizations over a period of 8 weeks.

This innovative technology of protein delivery by encapsulated cells was pioneered by Prof. P. Aebischer, President of EPFL in Lausanne, who has been an advisor to MaxiVAX since its foundation.

About MaxiVAX www.maxivax.ch

MaxiVAX is a Swiss-based clinical stage biotech company with a totally novel, patient-specific and personalized active immunotherapy product for cancer vaccination. The field of Immuno-Oncology has recently seen successes of first generation cancer immunotherapies which are paving the way for MaxiVAX's novel and competitive approach. The company's mission is to develop novel therapeutic vaccines that are more effective, personalized, and enable the patient's immune system to fight his/her own disease.

Its lead product MVX-ONCO-1 has completed a phase I trial in patients suffering from various solid cancers at an advanced stage. This trial confirmed a benign safety profile with encouraging efficacy data. The company will start a phase II trial in head and neck cancer in Switzerland in 2016 and is evaluating trials in other cancer types.

The company is managed by a world class team of scientists and business professionals. It is financed by private investors together with grants from public and private institutions.

Investor and Business Development Contact

Dimitrios Goundis Ph.D.

CEO

dgoundis@maxivax.ch

+41 79 866 1430

MaxiVAX SA

Rue de l'Athénée 24

CH-1206 Geneva

Switzerland

Media Contact

Nick Miles
Cabinet Privé de Conseils s.a.
Geneva, Switzerland
Phone : +41 22 321 45 40
Mobile : +41 79 678 76 26
E-mail : miles@cpc-pr.com

Edward Agne
The Communications Strategy Group Inc.
Cambridge, Mass, USA
Phone: +1 781 631 3117
Mobile: +1 781 888 0099
E-mail: edagne@comstratgroup.com